John W. Kozarich - Feb 28, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: Charles S. Berkman For: John W. Kozarich
Stock symbol
LGND
Transactions as of
Feb 28, 2022
Transactions value $
-$1,271
Form type
4
Date filed
3/1/2022, 03:34 PM
Previous filing
Jun 7, 2021
Next filing
Jun 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $91.9K +7.34K +21.09% $12.53 42.1K Feb 28, 2022 Direct
transaction LGND Common Stock Sale -$93.2K -908 -2.16% $102.62 41.2K Feb 28, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -7.34K -100% $0.00* 0 Feb 28, 2022 Common Stock 7.34K $12.53 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 31, 2012, and fully vested on the first anniversary of the grant date.